医药导报2026，Vol.45Issue(3)：378-382,5.DOI:10.3870/j.issn.1004-0781.2026.03.003
《评估和管理接受辅助生殖技术患者的心血管和产科风险的科学声明》解读
Interpretation of a Scientific Statement of Assessing and Addressing Cardiovascular and Obstetric Risks in Patients Undergoing Assisted Reproductive Technology
摘要
Abstract
In 2025,the American Heart Association(AHA)released a scientific statement evaluating and managing cardiovascular and obstetric risks in patients undergoing assisted reproductive technology(ART).The statement systematically summarized the short-and long-term impacts of ART procedures on individuals with cardiovascular disease(CVD),proposed a multidisciplinary collaborative assessment framework,and emphasized optimization of treatment strategies with reproductive endo-crinology and infertility(REI)specialists.It provided stage-specific management recommendations tailored to different CVD sub-types.This article synthesized the statement with international guidelines to offer clinical guidance for healthcare providers manag-ing CVD patients undergoing ART.关键词
评估和管理接受辅助生殖技术患者的心血管和产科风险的科学声明/辅助生殖技术/心血管疾病/产科风险Key words
Scientific statement of assessing and addressing cardiovascular and obstetric risks in patients undergoing assisted reproductive technology/Assisted reproductive technology/Cardiovascular diseases/Obstetric risks分类
医药卫生引用本文复制引用
康凤娇,韩丽珠,尹琪楠,边原..《评估和管理接受辅助生殖技术患者的心血管和产科风险的科学声明》解读[J].医药导报,2026,45(3):378-382,5.基金项目
成都市卫生健康委员会课题(2022005) （2022005）
2024年中国药理学会药源性疾病专委会药物安全研究项目(ADR2024MS17) （ADR2024MS17）
四川省药学会新质药学启航计划项目(scyxh20240701). （scyxh20240701）
